Method of treatment of hiv infection with vaccine
AssigneeGilead Sciences, Inc.
InventorsChristian BRANDER, Beatriz MOTHE, Ian MCGOWAN, Yovaninna ALARCÓN-SOTO
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for determining the magnitude of a subject's immune response against a HIVACAT T-cell immunogen (HTI or “HTI immunogen”) and whether the subject can avoid antiretroviral therapy (ART). These methods are helpful for treating human immunodeficiency virus (HIV) and/or deciding whether to administer, continue or stop antiretroviral therapy in a subject. The present disclosure also relates to antigens, compositions, and kits related to such methods.
Claims23
A method of treating a human immunodeficiency (HIV) infection in a human subject undergoing treatment with an antiretroviral therapy, comprising:
- (a) administering a HIVACAT T-cell immunogen (HTI) immunogen to the subject;
- (b) evaluating magnitude of the subject's immune response to the HTI immunogen;
- and
- (c) stopping treatment with the antiretroviral therapy if the subject has an elevated immune response to the HTI immunogen.
-7. (canceled)
-10. (canceled)
-13. (canceled)
-19. (canceled)
(canceled)
-61. (canceled)
Dependencies are inferred from the claim text.